January 4, 2023

Pharmaceutical Company to Produce Affordable Insulin in Petersburg

January 24, 2023

AmerisourceBergen Kicks Off Strategic Relationship with Civica

AmerisourceBergen will serve as Civica, Inc.’s exclusive distribution partner, providing supply chain support for Civica’s products and working to ensure that Civica’s crucial products reach its members across the country efficiently, reliably and securely. The partnership aims to accelerate mutual efforts to ensure the stability of supply of essential generic medicines nationwide.

Media Coverage

AmerisourceBergen Kicks Off Strategic Relationship with Civica
AmerisourceBergen Kicks Off Strategic Relationship with Civica

January 31, 2023

Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative

“As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,” said Ned McCoy, President and Chief Executive Officer of Civica. “Civica will deliver affordable, high-quality insulin, in the best pen platform, utilizing our new, state of the art manufacturing technology in Petersburg, Virginia.”

Media Coverage

Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative
Civica Partners with Ypsomed for Insulin Injection Pen

February 8, 2023

Utah-based Nonprofit Set to Open $140M Insulin Plant in Petersburg

Petersburg is at the center of a nonprofit’s push to lower sky-high insulin costs. Utah-based Civica Rx is in the final stages of building a $140 million insulin production plant in the city and expects to begin retail sales in 2024.

Media Coverage

Utah-based Nonprofit Set to Open $140M Insulin Plant in Petersburg
Game-changing Moves in Petersburg to Produce Affordable Insulin (Please advance video to 12:00)

March 18, 2023

California Selects Civica Rx as Its Insulin Manufacturing Partner

California’s partnership with Civica is a game changer,” said California Governor Gavin Newsom, announcing the state’s choice of Civica to manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative. “We are proud to be working with Civica to bring true price competition into the insulin drug market and ease the financial burden for Californians living with diabetes.”

(Please advance video to 22:00)

Media Coverage

California Selects Civica Rx as Its Insulin Manufacturing Partner
Governor Newsom Announces $30 Insulin Through CalRx
California Enters a Contract to Make Its Own Affordable Insulin
California Invests $50M to Partner with Civica Rx on Insulin Manufacturing

April 11, 2023

CivicaScript, SortPak Partner to Package & Deliver Medicines to Maximize Patient Convenience, Compliance & Savings

CivicaScript, which is dedicated to bringing lower-cost generic medicines to U.S. consumers, and SortPak, which delivers pre-sorted medications to patients at no extra cost to patients or health plans, are partnering to provide CivicaScript medicines in packaging designed to maximize patient convenience, savings and medication compliance.

Media Coverage

CivicaScript, SortPak Partner to Package & Deliver Medicines to Maximize Patient Convenience, Compliance & Savings
CivicaScript, SortPak Partner to Package & Deliver Medicines

April 20, 2023

What Spurred Lilly, Novo and Sanofi to Slash Insulin Prices? Expert Gives Her Take

The price cuts can be explained by a mix of factors, Leemore Dafny, Ph.D., wrote in a new analysis for The New England Journal of Medicine, titled “Falling Insulin Prices – What Just Happened?” One: The market is awaiting the entry of certain manufacturers that “don’t benefit from high prices.” Two: Government regulations are making it “costlier” for insulin manufacturers to keep charging their prior prices. Three: Public shaming.

Media Coverage

What Spurred Lilly, Novo and Sanofi to Slash Insulin Prices? Expert Gives Her Take
Falling Insulin Prices – What Just Happened?

May 3, 2023

CivicaRx Disrupts Out of Control Prescription Medication Pricing

Civica believes its model of rallying others to work together to ensure a reliable supply of fairly priced medicines is one that the wider pharmaceutical industry can ultimately support.

Media Coverage

CivicaRx Disrupts Out of Control Prescription Medication Pricing Through Market Solutions Rather Than Government Regulation